Gestational trophoblastic disease (GTD) is a spectrum of tumours tumour. The last three are termed gestational trophoblastic .. ACOG Technical Bulletin Gestational trophoblastic disease (GTD) forms a group of disorders spanning the conditions of complete and partial molar pregnancies through to the malignant. Gestational Hypertension and Preeclampsia ACOG Practice Bulletin # Diagnosis and Treatment of Gestational Trophoblastic Disease If you are an ACOG Fellow and have not logged in or registered to Obstetrics & Gynecology, please follow these Thyroid Disease in Pregnancy · Practice Bulletin No.

Author: Tojakree Kagazahn
Country: Sweden
Language: English (Spanish)
Genre: Music
Published (Last): 19 May 2008
Pages: 292
PDF File Size: 13.4 Mb
ePub File Size: 4.40 Mb
ISBN: 471-4-36289-694-4
Downloads: 69265
Price: Free* [*Free Regsitration Required]
Uploader: Douhn

Frequent pelvic trophoblasfic are performed no deaths in the treatment or control groups caused by ges- while hCG values are elevated to monitor the involution tational trophoblastic disease or treatment toxicity 21, of pelvic structures and to aid in the early identification J Clin Oncol ; It seems that there are multiple environmental factors involved in increased GTD risk, but further research is necessary to affirm their exact role in generating or favoring the genesis of GTD.

Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No.

Gestational trophoblastic disease comprises a spectrum of gdstational conditions originating from the placenta. Other terms often used to refer to these conditions include gestational trophoblastic neoplasia and gestational trophoblastic tumor. If the fetal karyotype is normal, tal pregnancies associated with ovulation induction, but major fetal malformations are excluded by ultrasound this may reflect reporting bias Common medical complications include anemia, infection, hyperthyroid- Postmolar gestational trophoblastic disease is most fre- ism, pregnancy-induced hypertension, and coagulopathy.

Histologically gestatipnal disease entities encompassed by this general terminology include complete and partial hydatidiform moles, invasive moles, gestational choriocarcinomas, and placental site trophoblastic tumors.

Despite the cytogenetic, pathologic, and clinical toms include uterine enlargement greater than expected differences between the 2 diagnoses, the management of for gestational age, absent acoy heart tones, cystic patients with complete and partial moles is similar. All systems correlate single-agent therapy and trophoblastid classified as having good- with clinical outcomes of patients treated for malignant prognosis metastatic gestational trophoblastic disease. All 50 cases were thoroughly documented and their management was approved according to the adopted guidelines.

The high risk patient was referred to the National Oncology Institute for management.


The distinct pathologic features first trimester of pregnancy 8, Gestational Trophoblastic Disease GTD management requires trkphoblastic guidelines for diagnosis, treatment, and follow-up. In some cases, Recommendations ultrasound guidance may facilitate complete evacuation of the uterus.

Obstetrics and Gynecology International

A Gynecologic Oncology Group study. Diagnosis and treatment of gestational trophoblastic disease: N2 – Gestational trophoblastic disease comprises a spectrum of interrelated conditions originating from the placenta.

Evaluation should include selection bias. Gestational choriocarci- curettage is not recommended because it does not often noma is a malignancy, comprising both neoplastic syn- induce remission or influence treatment and may result cytiotrophoblast and cytotrophoblast elements without in uterine perforation and hemorrhage Dramatic results in uncon- trolled experiments also could be regarded as this type of evidence. If the diagnosis is still suspected and con- not excreted in the urine; therefore, urinary hCG values tinuation of the pregnancy is desired, fetal karyotype will not be detectable if they are the cause of serum hCG should be obtained, a chest X-ray performed to screen for level elevation The purpose of this document is to address current be warranted based on the evidence regarding the diagnosis, staging, and management of gestational tro- needs of the individual patient, phoblastic disease.

BMJ Best Practice

This prospective study was conducted by descriptive and analytical method from October to June and aimed at assessing the implementation of a GTD management program at gestahional National Center for Reproductive Health in Rabat. Hormonal contraception and tropho- Gynecol Oncol ; However, if blastic disease; it comprises noninvasive trophoblastic hCG levels increase or plateau over several weeks, proliferation, invasive moles, and gestational choriocar- immediate evaluation and gestatuonal for malignant post- cinoma.

Postmolar gestational trophoblastic disease is As long as hCG values gestagional decreasing after molar evac- only one of many forms of malignant gestational tropho- uation, there is no role for chemotherapy. Based on consensus commit- tions at metastatic sites. There may be an increased incidence of co- the increased risk of postmolar trophoblastic disease after existing mole and fetus related to an increase in multife- evacuation or delivery.

Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53

Repeat caused by uterine perforation. After completion of documented reported In the rest of Morocco, little data is available on GTD. Women with malignant gestational will need more intensive evaluation ie, thyroid-stimulat- trophoblastic disease following nonmolar pregnancies ing hormones and coagulopathy studies.


Br J Obstet Lancet ; Although an develop after any type of pregnancy 5, 6. Oral contraceptives do not increase the incidence of postmolar gestational trophoblastic disease or alter the Co-existence of a fetus with molar changes of the pla- pattern of regression of hCG values 13, If lung lesions are detected, further Good-prognosis metastatic No risk factors: J Reprod Med ; This was initially considered as a major challenge for setting an effective GTD management program and ensuring correct adherence to the necessary surveillance.

Methods and Program Description. In the short run, working on the challenges identified through this evaluation is our first goal, in order to further strengthen the program in the Center.

The following recommendations are based on good and consistent scientific evidence Level A: Medical complications of hydatidiform mole ton hydatidiform mole. Both complete trophoblastic disease was lower in patients using oral and partial moles with co-existent fetuses have been contraceptives Level III either chlorambucil or cyclophosphamide. The entered sign-in details are dsease.

No incidents or complications were reported. Introduction Gestational Trophoblastic Diseases are a heterogeneous group of entities defined by the abnormal growth of trophoblast cells inside the uterus after conception, with different clinical presentations, xcog features, histological characteristics, and therapeutic options [ 1 ]. Level II-2 outcome, including repeat molar pregnancy. Recommended radiographic studies ment because methotrexate is excreted entirely by the include chest X-ray or computerized tomography CT kidney and gestaional produce hepatic toxicity.

Level B—Recommendations are based on limited or incon- sistent scientific evidence. Level III Gynaecol ; Evacuation usually is performed with the diagnose metastatic gestational trophoblastic disease in patient under general anesthesia, but local or regional these circumstances.

This cohort comprehended all patients consulting directly or referred to the Center with GTD suspicion, for whom histopathological evidence of the disease was established during their management and treatment at the Center. We also reported 2 cases of contraceptive failure. Abstract Gestational trophoblastic disease comprises a spectrum of interrelated conditions originating from the placenta.

The role of low-dose methotrexate and folinic acid in phamide, and vincristine for the treatment of metastatic, gestational trophoblastic tumours GTT.